Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
506.50    1.50 (0.30%)
Bid:
505.50
Ask:
508.50
Spread: 3.00 (0.593%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Acquisition

9 Jun 2022 07:06

RNS Number : 2932O
Tate & Lyle PLC
09 June 2022
 

FOR IMMEDIATE RELEASE

 

 

Tate & Lyle completes acquisition of dietary fibre business in China

 

London, UK, 9 June 2022 - Tate & Lyle PLC (Tate & Lyle), a leading global provider of food and beverage ingredients and solutions, announces that it has today completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd (Quantum), a leading prebiotic dietary fibre business located in China. The signing of a conditional agreement for this acquisition was announced on 31 March 2022.

 

Nick Hampton, Chief Executive of Tate & Lyle, said:

"This acquisition significantly strengthens our fortification platform and our position as a leading global player in dietary fibres, while extending our presence in China and Asia. FOS and GOS fibres are highly complementary to our existing fibre portfolio and will allow us to offer a broader range of solutions to our customers across key markets. 

 

We are delighted to welcome our new colleagues from Quantum to Tate & Lyle. Quantum is a great fit with our growth strategy and our purpose of Transforming Lives through the Science of Food, giving us more opportunities to improve gut health and provide fibre fortification for consumers across the world."

 

ENDS

Notes to editors

1.  FOS are fructo-oligosaccharides and GOS are galacto-oligosaccharides,

2. Read the initial announcement press release: Tate & Lyle to acquire leading dietary fibre business in China - 31 March 2022

 

For more information contact Tate & Lyle PLC

Investor Relations:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Media:

Nick Hasell, FTI Consulting Mobile: +44 (0) 7825 523 383

 

About Tate & Lyle

 

Tate & Lyle is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fortification, we develop solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.

 

We have more than 3,000 employees working in around 60 locations across 30 countries. Tate & Lyle's purpose is Transforming Lives Through the Science of Food and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year ended 31 March 2021, Tate & Lyle's revenue from continuing operations totaled £1.2 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, LinkedIn or Facebook.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQGLGDLDGGDGDC
Date   Source Headline
21st May 202612:15 pmRNSForm 8.3 - Tate & Lyle plc
21st May 202612:06 pmBUSForm 8.3 - Tate & Lyle
21st May 202611:53 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
21st May 202611:22 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
21st May 202611:13 amRNS20260520_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
21st May 202611:11 amRNS20260520_TATE & LYLE_8.5 EPT RI_UK_MLI
21st May 202611:09 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
21st May 202611:01 amRNSForm 8.3 TATE & LYLE PLC
21st May 202610:28 amRNSForm 8.3 - Tate & Lyle Plc
21st May 20268:29 amRNSForm 8.5 (EPT/RI)
21st May 20267:00 amRNSFinal Results
20th May 20264:28 pmRNSForm 8.5 - Tate & Lyle Plc
20th May 20264:26 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
20th May 20263:27 pmRNSForm 8.3 Tate & Lyle plc
20th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20262:49 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20262:03 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
20th May 20261:52 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20261:28 pmRNSForm 8.3 - Tate & Lyle plc
20th May 20261:22 pmRNSForm 8.3 TATE & LYLE PLC
20th May 202612:26 pmRNSForm 8.3 Tate & Lyle Plc
20th May 202612:05 pmRNSForm 8.3 - Tate & Lyle plc
20th May 202611:59 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
20th May 202611:58 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
20th May 202611:47 amRNSForm 8.3- TATE & LYLZ
20th May 202611:35 amRNS20260519_TATE & LYLE_8.5 EPT RI_UK_MLI
20th May 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle Plc
20th May 202611:02 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
20th May 20269:21 amRNSForm 8.5 (EPT/RI)
20th May 20269:18 amRNSForm 8.3 - Tate and Lyle PLC
20th May 20267:33 amRNSForm 8.5 (EPT/RI) - Amend - Tate & Lyle PLC
19th May 20265:59 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
19th May 20265:51 pmRNSForm 8.3 - Tate & Lyle PLC
19th May 20263:39 pmRNSForm 8.3 TATE & LYLE PLC
19th May 20263:25 pmRNSForm 8.3 - Tate & Lyle PLC
19th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
19th May 20262:08 pmRNSForm 8.3 - Tate & Lyle plc
19th May 20262:00 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
19th May 202611:53 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
19th May 202611:52 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
19th May 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
19th May 202611:08 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
19th May 202611:06 amRNSForm 8.3 Tate & Lyle
19th May 202611:05 amRNSForm 8.3 - Tate & Lyle plc
19th May 202610:53 amBUSForm 8.3 - Tate & Lyle plc
19th May 202610:45 amRNSForm 8.3 - Tate & Lyle PLC
19th May 202610:19 amRNS20260518_TATE & LYLE_8.5 EPT RI_UK_MLI
19th May 20269:32 amRNSForm 8.5 (EPT/RI)
18th May 20265:50 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
18th May 20264:48 pmRNS20260514_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.